10-Q: NovAccess Global Reports Net Income of $1.3 Million for Q1 2024 Amidst Debt and Financing Challenges

NovAccess Global reports a net income of $1.3 million for the quarter ended December 31, 2023, a significant turnaround from the previous year's loss, but faces ongoing liquidity and debt challenges.

Summary

• NovAccess Global Inc. reported a net income of $1.3 million for the three months ended December 31, 2023, compared to a net loss of $2.63 million for the same period in 2022.
• The improvement was primarily due to a $1.86 million gain on the change in derivative liability and a $228,640 improvement in interest expense.
• Selling, general, and administrative expenses decreased by $274,306 to $207,849, mainly due to reduced consulting and legal/accounting fees.
• Research and development expenses increased slightly by $14,734 to $49,697.
• The company had a working capital deficit of $6.43 million as of December 31, 2023, an improvement from the $7.80 million deficit as of September 30, 2023.
• NovAccess is facing liquidity challenges and needs to raise at least $3.0 million by December 31, 2024, to finance operations and meet loan obligations.
• A securities purchase agreement with Sumner Global LLC is in place for $3.63 million in stock purchase and $7.05 million in loans, but its completion is not guaranteed.
• The company is in default on several convertible promissory notes due to late filing of its annual report, potentially triggering penalties and accelerated payment demands.
• Management acknowledges material weakness in disclosure controls and procedures.

Sentiment

Score: 5

Explanation: The company shows a positive net income, but is offset by the going concern risk, default on debt, and material weakness in internal controls.

Positives

• The company achieved a net income of $1.3 million for the quarter, a substantial turnaround from the previous year's loss.
• The working capital deficit decreased by $1.37 million, indicating improved financial management.
• The company has a potential financing agreement with Sumner Global LLC for $3.63 million in stock purchase and $7.05 million in loans.
• Selling, general, and administrative expenses decreased by $274,306, reflecting cost-cutting measures.

Negatives

• The company has a significant working capital deficit of $6.43 million.
• The company is in default on several convertible promissory notes, potentially leading to penalties and accelerated payment demands.
• The Sumner Global LLC financing is contingent and not guaranteed.
• The company acknowledges a material weakness in its disclosure controls and procedures.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• Failure to complete the Sumner Global LLC financing could severely impact the company's liquidity.
• Default on convertible promissory notes could lead to significant financial penalties and dilution of existing shareholders.
• Material weakness in disclosure controls and procedures raises concerns about the reliability of financial reporting.
• The company needs to raise at least $3.0 million through December 31, 2024, to finance its ongoing operations, complete its IND application to the FDA and to make payments under its loan agreements.

Future Outlook

The company plans to submit an IND application in 2024 if funding is available and needs to raise at least $3.0 million through December 31, 2024. The company expects to raise capital through the issuance of additional common stock as well as obtaining additional debt as needed.

Management Comments

• Management believes the existing shareholders, prospective new investors and lenders will provide the additional cash needed to meet the Company's obligations as they become due and will allow the development of its business.
• Messrs. Irvin and Laird concluded that the Company's disclosure controls and procedures were not effective as of December 31, 2023, as a result of a material weakness.

Industry Context

NovAccess is operating in the competitive biopharmaceutical industry, focusing on novel immunotherapies for brain tumor patients. The company's success depends on obtaining FDA approval for its drug product and securing sufficient funding for clinical trials and commercialization.

Comparison to Industry Standards

• It is difficult to compare NovAccess to industry standards due to its early stage of development and lack of revenue.
• Many comparable companies are larger and have established revenue streams, making direct comparisons challenging.
• However, the company's focus on immunotherapies for brain tumors aligns with a growing trend in the biopharmaceutical industry.
• Companies like Northwest Biotherapeutics and Immatics are also working on similar therapies, but their clinical and financial status may differ significantly.

Related Party Transactions

• During the quarter ended December 31, 2023, the Company issued 108,750 shares to a related party for services provided, amounting to $2,121 recorded at the fair value of shares on the respective grant date.
• On December 21, 2023, our Chairman, John A. Cassarini loaned the Company $10,000 to address short-term cash need.
• Our Chief Financial Officer, Neil J. Laird loaned the Company $1,000.
• On January 26, 2024, Jason Anderson loaned the Company a further $2,000 to address short-term cash needs.

Stakeholder Impact

• Shareholders face potential dilution from future stock issuances and risks associated with the company's financial instability.
• Employees' job security is uncertain due to the company's dependence on securing additional funding.
• The company's ability to develop and commercialize its drug product could impact brain tumor patients and the broader healthcare community.
• Creditors face the risk of default and potential losses on their investments.

Next Steps

• The company plans to submit an IND application in 2024 if funding is available.
• The company needs to secure the Sumner Global LLC financing or find alternative funding sources.
• The company needs to address the defaults on convertible promissory notes.
• The company needs to remediate the material weakness in disclosure controls and procedures.

Key Dates

Keywords

convertible notes, financing, liquidity, net income, NovAccess Global, biopharmaceutical, Sumner Global, default, working capital, derivative liability